Bloqueios químicos para o tratamento da espasticidade na paralisia cerebral
DOI:
https://doi.org/10.11606/issn.2317-0190.v17i2a103314Palavras-chave:
Espasticidade Muscular, Paralisia Cerebral, Toxina Botulínica Tipo AResumo
Os bloqueios químicos são considerados armas importantes no moderno tratamento da espasticidade tanto em adultos como em crianças. Eles podem ser realizados com fenol, com toxina botulínica do tipo A ou ainda com ambos, os chamados bloqueios mistos. Neste artigo discutiremos em detalhes os diferentes tipos de bloqueios químicos utilizados para o tratamento da espasticidade.
Downloads
Referências
Jozefczyk PB. The management of focal spasticity. Clin Neuropharmacol. 2002;25(3):158-73.
Kerr Graham H, Selber P.Musculoskeletal aspects of cerebral palsy. J Bone Joint Surg Br. 2003;85(2):157-66.
Sharan D. Recent advances in management of cerebral palsy. Indian J Pediatr. 2005;72(11):969-73.
Matthews DJ, Balaban B. Management of spasticity in children with cerebral palsy. Acta Orthop Traumatol Turc. 2009;43(2):81-6.
Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol. 2009;11(3):153-61.
Kolaski K, Ajizian SJ, Passmore L, Pasutharnchat N, Koman LA, Smith BP. Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population. Am J Phys Med Rehabil. 2008;87(7):556-66.
Tilton AH. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol. 2004;11(1):58-65.
Morrison JE Jr, Matthews D, Washington R, Fennessey PV, Harrison LM. Phenol motor point blocks in children: plasma concentrations and cardiac dysrhythmias. Anesthesiology. 1991;75(2):359-62.
Elovic E. Principles of pharmaceutical management of spastic hypertonia. Phys Med Rehabil Clin N Am. 2001;12(4):793-816.
Gormley ME Jr, Krach LE, Piccini L. Spasticity management in the child with spastic quadriplegia. Eur J Neurol. 2001; 8 Suppl 5:127-35.
Patel DR, Soyode O. Pharmacologic interventions for reducing spasticity in cerebral palsy. Indian J Pediatr. 2005;72(10):869-72.
Petrillo C, Chu D, Davis S. Phenol block of the tibial nerve in the hemiplegic patient. Orthopedics. 1980;3:871-4.
Glenn M. Nerve blocks. In: Glenn MB, Whyte J eds. The Practical Management of Spasticity in Children and Adults. Philadelphia: Lea & Febiger, 1990. p. 230.
Gracies JM, Elovic E, McGuire JR, Zorowitz R. Traditional Pharmacologic Treatments for spasticity part I: local treatments. In: Brasher A, Mayer NH. Spasticity: etiology, evaluation, management, and the role of botulinum toxin. New York: Wemove; 2008. p.119-41.
Satkunam LE. Rehabilitation medicine: 3. Management of adult spasticity. CMAJ. 2003;169(11):1173-9.
O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain. 2002;18(6 Suppl):S182-90.
Mooney JF 3rd, Koman LA, Smith BP. Pharmacologic management of spasticity in cerebral palsy. J Pediatr Orthop. 2003;23(5):679-86.
Tilton AH. Therapeutic interventions for tone abnormalities in cerebral palsy. NeuroRx. 2006;3(2):217-24.
Sposito MMM. Toxina Botulínica do tipo A: mecanismo de ação. Acta Fisiatr. 2009;16(1):25-37. Doi: https://doi.org/10.11606/issn.2317-0190.v16i1a103037
Poli MA, Lebeda FJ. An overview of clostridial neurotoxins. In: Massaro EJ, editor. Handbook of neurotoxicology. Totowa: Human Press; 2002. p. 293-304.
Aoki KR. Botulinum toxin: a successful therapeutic protein. Curr Med Chem. 2004;11(23):3085-92.
Hicks RP, Hartell MG, Nichols DA, Bhattacharjee AK, van Hamont JE, Skillman DR. The medicinal chemistry of botulinum, ricin and anthrax toxins. Curr Med Chem. 2005;12(6):667-90.
Frenkl TL, Rackley RR. Injectable neuromodulatory agents: botulinum toxin therapy. Urol Clin North Am. 2005;32(1):89-99.
Wenzel RG. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm. 2004;61(22 Suppl 6):S5-10.
Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26(5):785-93.
Silberstein S. Botulinum neurotoxins: origins and basic mechanisms of action. Pain Pract. 2004;4 Suppl 1:S19-26.
Lipham WJ. What is botulinum toxin and how does it works? In: Lipham WJ. Cosmetic and clinical application of Botulinum Toxin. Thorofare: Slack; 2004. p.5-9.
Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002;27(11):552-8.
de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA. 1999;96(6):3200-5.
Meunier FA, Herreros J, Schiavo G, Poulain B, Molgó J. Molecular mechanism of action of botulinal neurotoxins and the synaptic remodeling they induce in vivo at skeletal neuromuscular junction. In: Massaro EJ. Handbook of neurotoxicology. Totowa: Human Press; 2002. p. 305-47
Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-8.
Dressler D, Adib Saberi FA. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53(1):3-9.
Yoshida K, Kaji R, Kubori T, Kohara N, Iizuka T, Kimura J. Muscle afferent block for the treatment of oromandibular dystonia. Mov Disord. 1998;13(4):699-705.
Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248 Suppl 1:3-10.
Yablon SA. Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders. Phys Med Rehabil Clin N Am. 2001;12(4):833-74.
Molenaers G, Desloovere K, Eysse M, De Cat J, Jonkers I, De Cock P. Botulium toxin type A treatment of cerebral palsy: an integrated approach. Eur J Neurol. 1999;6(Suppl 4):S51-S57.
Graham HK, Aoki KR, Autti-Rämö I, Boyd RN, Delgado MR, Gaebler-Spira DJ, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000 Feb;11(1):67-79.
Pascual-Pascual SI, Herrera-Galante A, Póo P, García-Aymerich V, Aguilar-Barberà M, Bori-Fortuny I, et al. Guidelines for the treatment of child spasticity using botulinum toxin. Rev Neurol. 2007;44(5):303-9.
Ward AB, Molenaers G, Colosimo C, Berardelli A. Clinical value of botulinum toxin in neurological indications. Eur J Neurol. 2006;13 Suppl 4:20-6.
Tilton AH. Approach to the rehabilitation of spasticity and neuromuscular disorders in children. Neurol Clin. 2003;21(4):853-81.
Hart DA. Use of botulinum toxin in spasticity. Phys Med Rehabil. 2000;14(2):247-61.
Gaebler-Spira D, Revivo G.The use of botulinum toxin in pediatric disorders. Phys Med Rehabil Clin N Am. 2003;14(4):703-25.
Pascual-Pascual SI, Pascual-Castroviejo I. Safety of botulinum toxin type A in children younger than 2 years. Eur J Paediatr Neurol. 2009;13(6):511-5.
Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm. 2008;115(4):607-16.
Balkrishnan R, Camacho FT, Smith BP, Shilt JS, Jacks LK, Koman LA, et al. Cost impact of botulinum toxin use in Medicaid-enrolled children with cerebral palsy. J South Orthop Assoc. 2002;11(2):71-9.
Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1691-8.
Wemove Spasticity Study Group. Dosing, administration and a treatment algorithm for use of botulinum toxin type A for adult onset muscle overactivity. In: Mayer N, Sunpson D, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. New York: We Move; 2002. p.154-66.
Wemove Spasticity Study Group. Dosing tables for adult spasticity (revised 2005). New York: WeMove; c2010 [cited 2010 Jan 15]. Available from: http://www.mdvu.or/classrooms/cme/chemd3/pediatricspastdosing.pdf
Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol. 2006;21(3):189-92.
Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56(1):80-99.
Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365(6442):160-3.
Rossetto O, Deloye F, Poulain B, Pellizzari R, Schiavo G, Montecucco C. The metallo-proteinase activity of tetanus and botulism neurotoxins. J Physiol Paris. 1995;89(1):43-50.
O'Brien C. Management of spasticity associated with stroke. In: O'Brien C, Yablon S, editors. Management of spasticity with botulinum toxin. Littleton: Postgraduate Institute for Medicine; 1995. p.7-10.
Hatheway CL, Dang C. Immunogenicity of neutoxins of clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Decker; 1994. p.93-107.
Aoki KR, Francis J, Reynolds H. Comparison of the therapeutic windows of different botulinum neurotoxin preparations in an animal model. Neurology. 2003;60(suppl 1):A212- A213.
Aoki KR, Wheeler LA. A comparison of the efficacy and safety of BOTOX and DYSPORT in mice. Ann Neurol. 2001;50(3 Suppl):S32.
Borodic GE, Pearre LB, Smith KL, Phelau AT, Ferrante R. Botulinum B toxin as an alternative to botulinum A toxin: a histological study. Ophthal Plast Reconstr Surg. 1995;9:182-90.
Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg. 1998;24(11):1179-80.
Benedetto AV. The cosmetic uses of botulinum toxin type A. Int J Dermatol. 1999;38(9):641-55.
Manaloto RM, Alster TS. Periorbital rejuvenation: a review of dermatologic treatments. Dermatol Surg. 1999;25(1):1-9.
Garcia A, Fulton JE Jr. Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study. Dermatol Surg. 1996;22(1):39-43.
Oliveira MV, Oliveira AP. Toxina botulínica no tratamento de rugas faciais. São Paulo: Cosmedical; c2010 [citado 2010 Abr 15]. Disponível em: http://www.cosmedical.com.br/botox.htm
Zechmeister M, Dal'Forno TO. Conservação, diluição e estocagem após a diluição. In: Hexsel D, Almeida AT. Cosmetic use botulinum toxin. Porto Alegre: Age; 2000. p.43-5.
Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord. 1994;9(1):31-9.
Ahn KY, Park MY, Park DH, Han DG. Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans. Plast Reconstr Surg. 2000;105(2):778-84.
Hamjian JA, Walker FO. Serial neurophysiological studies of intramuscular botulinum - A toxin in humans. Muscle Nerve. 1994;17(12):1385-92.
Hexsel D, Mazzuco R, Zechmeister M, Hexsel C. Complications and adverse effects: diagnosis and treatment. In: Hexsel D, Almeida AT. Cosmetic use of botulinum toxin. Porto Alegre: Age; 2000. p.233-9.
Moore P, Naumann M. Handbook of botulinum toxin treatment. Maldem: Blackwell Sciences; 2003.
Böni R, Kreyden OP, Burg G. Revival of the use of botulinum toxin: application in dermatology. Dermatology. 2000;200(4):287-91.
Fields KA. Skin breakthroughs in the year 2000. Int J Fertil Womens Med. 2000;45(2):175-81.
Borodic GE. Botulinum A toxin for (expressionistic) ptosis overcorrection after frontalis sling. Ophthal Plast Reconstr Surg. 1992;8(2):137-42.
Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg. 1999;103(2):701-13.
Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. 1993;16(9):964-9.
Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil. 2009;90(1):9-16.
Heinen F, Molenaers G, Fairhurst C, Carr LJ, Desloovere K, Chaleat Valayer E, et al. European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol. 2006;10(5-6):215-25.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2010 Acta Fisiátrica
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
